Halozyme Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Halozyme Therapeutics has a total shareholder equity of $452.7M and total debt of $1.5B, which brings its debt-to-equity ratio to 332.3%. Its total assets and total liabilities are $2.1B and $1.7B respectively. Halozyme Therapeutics's EBIT is $477.0M making its interest coverage ratio 60.1. It has cash and short-term investments of $666.3M.
Key information
332.3%
Debt to equity ratio
US$1.50b
Debt
| Interest coverage ratio | 60.1x |
| Cash | US$666.31m |
| Equity | US$452.70m |
| Total liabilities | US$1.67b |
| Total assets | US$2.12b |
Recent financial health updates
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Recent updates
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Nov 20Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 05Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29Halozyme Therapeutics: Behind The Pullback
Oct 22Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Financial Position Analysis
Short Term Liabilities: HALO's short term assets ($1.1B) exceed its short term liabilities ($108.8M).
Long Term Liabilities: HALO's short term assets ($1.1B) do not cover its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: HALO's net debt to equity ratio (185.1%) is considered high.
Reducing Debt: HALO's debt to equity ratio has increased from 26% to 332.3% over the past 5 years.
Debt Coverage: HALO's debt is well covered by operating cash flow (26.8%).
Interest Coverage: HALO's interest payments on its debt are well covered by EBIT (60.1x coverage).